Caris Life Sciences (NASDAQ:CAI) Given New $28.00 Price Target at Robert W. Baird

Caris Life Sciences (NASDAQ:CAI) had its target price upped by research analysts at Robert W. Baird from $26.00 to $28.00 in a research note issued on Friday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Robert W. Baird’s price target suggests a potential upside of 45.53% from the company’s previous close.

A number of other equities analysts also recently issued reports on CAI. Weiss Ratings reiterated a “sell (d)” rating on shares of Caris Life Sciences in a research report on Monday, December 29th. Canaccord Genuity Group increased their target price on Caris Life Sciences from $28.00 to $30.00 and gave the company a “hold” rating in a report on Monday, December 22nd. Wall Street Zen cut Caris Life Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Finally, Evercore set a $38.00 target price on shares of Caris Life Sciences in a research note on Monday, January 5th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $33.50.

Caris Life Sciences Stock Performance

Shares of NASDAQ CAI opened at $19.24 on Friday. The stock has a market capitalization of $5.43 billion and a P/E ratio of -41.83. The company has a debt-to-equity ratio of 0.79, a current ratio of 9.93 and a quick ratio of 9.36. The business’s fifty day moving average price is $24.58. Caris Life Sciences has a 1 year low of $17.15 and a 1 year high of $42.50.

Caris Life Sciences (NASDAQ:CAI) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.27. During the same quarter last year, the company posted ($1.73) earnings per share. The firm’s quarterly revenue was up 125.4% on a year-over-year basis.

Insider Transactions at Caris Life Sciences

In other Caris Life Sciences news, insider Luke Thomas Power sold 62,250 shares of Caris Life Sciences stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $26.58, for a total transaction of $1,654,605.00. Following the transaction, the insider directly owned 99,571 shares of the company’s stock, valued at $2,646,597.18. The trade was a 38.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 7.80% of the company’s stock.

Institutional Trading of Caris Life Sciences

Several institutional investors have recently made changes to their positions in the company. Global Retirement Partners LLC lifted its holdings in Caris Life Sciences by 99,900.0% in the fourth quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock valued at $27,000 after acquiring an additional 999 shares during the last quarter. Olistico Wealth LLC acquired a new position in shares of Caris Life Sciences in the 4th quarter valued at $31,000. MetLife Investment Management LLC lifted its stake in shares of Caris Life Sciences by 84.0% in the 4th quarter. MetLife Investment Management LLC now owns 1,654 shares of the company’s stock valued at $45,000 after purchasing an additional 755 shares during the last quarter. Aster Capital Management DIFC Ltd purchased a new position in shares of Caris Life Sciences during the 4th quarter worth $67,000. Finally, Federated Hermes Inc. acquired a new stake in shares of Caris Life Sciences during the 4th quarter worth about $81,000.

Key Headlines Impacting Caris Life Sciences

Here are the key news stories impacting Caris Life Sciences this week:

• Positive Sentiment: Q4 earnings and revenue beat—Caris reported GAAP EPS of $0.28 (vs. ~$0.01 consensus) and Q4 revenue of roughly $292–293M, up ~125% year-over-year, showing rapid top-line recovery and a swing to profitability. This beat and margin trend support upward price action. Caris Q4 & 2025 Results
• Positive Sentiment: Interim Achieve 1 readout strongly supports Caris Detect—an internal interim analysis showed whole-genome sequencing (WGS)-based Caris Detect delivered superior sensitivity and specificity versus methylation-based approaches, a key clinical validation ahead of launch that materially de-risks the MCED (multi-cancer early detection) opportunity. This is a major near-term commercial catalyst. Achieve 1 Interim Readout
• Positive Sentiment: Baird initiates coverage with an Outperform—fresh analyst coverage with a positive rating can increase investor interest and provide incremental buy-side demand. Baird Initiates Coverage
• Positive Sentiment: Product innovation—Caris added an AI-powered breast cancer signature to its Caris Molecular Tumor Board Report, enhancing its product set for clinicians and potentially expanding clinical utility and revenue per test. AI Breast Cancer Signature
• Neutral Sentiment: FY‑2026 revenue guidance updated to ~$1.0B–$1.02B, modestly above consensus (~$995.8M); management is guiding continued high growth but investors will watch margin and cadence of MCED roll-out. 2026 Guidance
• Neutral Sentiment: Short-interest data reported is noisy/erroneous in the feed (shows zeros) and is not a meaningful signal; monitor reliable short-interest updates for potential squeezes. (no link)
• Negative Sentiment: Valuation & technical context—despite today’s pop, CAI remains below its 50‑day moving average and off its one‑year high; investors should weigh execution risk of commercializing Caris Detect, regulatory review, and the company’s path to sustained profitability. (background datapoints)

Caris Life Sciences Company Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.